← Back to Search

Stem Cell Therapy

CD34+ bone marrow stem cells intravitreal for Retinitis Pigmentosa

Phase 1
Waitlist Available
Led By Susanna s Park, MD PhD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age >18 years of age
Vision loss from macular degeneration, retinitis pigmentosa, retinal vein occlusion, or diabetic retinopathy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day to 6 months
Awards & highlights

Study Summary

This trial is to see if it's safe to inject stem cells from bone marrow into the eye to treat blindness from various retinal conditions.

Who is the study for?
This trial is for adults over 18 with vision loss from conditions like macular degeneration or diabetic retinopathy. Participants must have a visual acuity ranging from 20/100 to hand movement and the affected eye should be the one with worse vision. They shouldn't have had certain eye treatments in the last 6 months, no blood disorders, active diseases, or be on immunosuppressive therapy.Check my eligibility
What is being tested?
The study tests injecting CD34+ stem cells directly into the eye of patients who are blind due to various retinal diseases. It aims to assess if this approach is safe and can feasibly improve sight.See study design
What are the potential side effects?
Potential side effects may include discomfort at injection site, inflammation inside the eye, increased intraocular pressure, bleeding, infection risk post-procedure and possible immune reaction.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am older than 18 years.
Select...
I have vision loss due to a specific eye condition.
Select...
I haven't had treatments for eye swelling or abnormal blood vessels in the eye in the last 6 months.
Select...
I am not on any immunosuppressive therapy.
Select...
I have had vision loss for more than 3 months.
Select...
I do not have any active eye or systemic diseases.
Select...
I do not have any blood clotting or blood disorders.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence and severity of ocular adverse events
Secondary outcome measures
The number of stem cells isolated and injected into the study eye
Other outcome measures
Incidence and severity of systemic adverse events

Trial Design

1Treatment groups
Experimental Treatment
Group I: Stem cell treatedExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
908 Previous Clinical Trials
4,704,100 Total Patients Enrolled
2 Trials studying Retinitis Pigmentosa
442 Patients Enrolled for Retinitis Pigmentosa
Susanna s Park, MD PhDPrincipal InvestigatorUniversity of California Davis Eye Center

Media Library

CD34+ bone marrow stem cells (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT01736059 — Phase 1
Retinitis Pigmentosa Research Study Groups: Stem cell treated
Retinitis Pigmentosa Clinical Trial 2023: CD34+ bone marrow stem cells Highlights & Side Effects. Trial Name: NCT01736059 — Phase 1
CD34+ bone marrow stem cells (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01736059 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this study's eligibility criteria restrict those aged eighteen or older?

"This medical trial will include patients that are at least 18 years old and not older than 100."

Answered by AI

Is there an opportunity for me to participate in this experiment?

"Eligibility criteria for this clinical trial necessitates that potential participants possess retinitis pigmentosa and be between 18 to 100 years of age. Approximately 15 candidates will be selected in total."

Answered by AI

Are there any federal regulations for intravitreal injections of CD34+ bone marrow stem cells?

"Owing to the limited clinical data surrounding CD34+ bone marrow stem cells intravitreal, it was assigned a score of 1 on our safety scale. This assessment is reflective of its Phase 1 status."

Answered by AI

Is this research study recruiting participants at this time?

"The data from clinicaltrials.gov shows that this particular trial, which was originally added on July 1st 2012 and last updated on August 8th 2022, is no longer accepting candidates. Fortunately, there are 299 other trials in need of participants currently available."

Answered by AI

Who else is applying?

What state do they live in?
Florida
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
~2 spots leftby Oct 2025